Crucell licenses PER.C6 to Immuno-Biological Laboratories

By Elaine Rigoli

Tampa, Fla., June 20 - Crucell NV announced that it has signed a PER.C6 research license agreement with Immuno-Biological Laboratories Co., Ltd., a Japanese company specializing in the production of antibody-based reagents for life-science research.

Under the agreement, Immuno-Biological Laboratories will pay a license issuance fee and annual maintenance fees. Further financial details were not disclosed.

Immuno-Biological Laboratories will use PER.C6 to develop a range of recombinant protein products that can be used as laboratory reagents, according to a news release.

Immuno-Biological has also obtained an option to a commercial license to manufacture the reagents and offer them for sale for laboratory research purposes.

Based in Leiden, the Netherlands, Crucell is a biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.